CIBC Asset Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.45M Buy
30,224
+654
+2% +$28.6K ﹤0.01% 672
2025
Q4
$1.14M Buy
29,570
+43
+0.1% +$1.64K ﹤0.01% 692
2025
Q3
$1.04M Buy
29,527
+121
+0.4% +$4.38K ﹤0.01% 670
2025
Q2
$1.06M Buy
29,406
+2,334
+9% +$77.3K ﹤0.01% 662
2025
Q1
$843K Buy
27,072
+953
+4% +$30.2K ﹤0.01% 688
2024
Q4
$666K Buy
26,119
+1,028
+4% +$27.3K ﹤0.01% 710
2024
Q3
$710K Buy
25,091
+905
+4% +$25.1K ﹤0.01% 698
2024
Q2
$638K Buy
24,186
+12,537
+108% +$348K ﹤0.01% 704
2024
Q1
$354K Sell
11,649
-210
-2% -$6.19K ﹤0.01% 790
2023
Q4
$333K Buy
+11,859
New +$326K ﹤0.01% 789
2023
Q1
Sell
-14,157
Closed -$559K 1124
2022
Q4
$559K Sell
14,157
-11,709
-45% -$489K ﹤0.01% 716
2022
Q3
$1.04M Buy
25,866
+46
+0.2% +$1.97K ﹤0.01% 663
2022
Q2
$1.08M Sell
25,820
-931
-3% -$38.2K ﹤0.01% 645
2022
Q1
$1.04M Buy
26,751
+92
+0.3% +$3.61K ﹤0.01% 687
2021
Q4
$1.06M Buy
26,659
+2,343
+10% +$91K ﹤0.01% 679
2021
Q3
$879K Buy
24,316
+1,070
+5% +$41.6K ﹤0.01% 710
2021
Q2
$953K Buy
23,246
+5
+0% +$213 ﹤0.01% 691
2021
Q1
$1.01M Buy
+23,241
New +$1.1M ﹤0.01% 661

Other funds holding RPRX

CIBC Asset Management's RPRX Position: Q1 2026 in Review

CIBC Asset Management increased its Royalty Pharma (RPRX) stake by 2.2% in Q1 2026, buying an estimated $28.6K and bringing the position to 30,224 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #672.

CIBC Asset Management first reported a position in RPRX in Q1 2021 and has held it in 18 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • CIBC Asset Management held 30,224 shares of Royalty Pharma worth $1.45M as of Q1 2026.
  • CIBC Asset Management bought 654 Royalty Pharma shares in Q1 2026, an estimated $28.6K.
  • Royalty Pharma made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #672 holding.
  • CIBC Asset Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 18 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.